Altimmune (ALT) recently released pemvidutide's 48-week topline results from their IMPACT Phase IIb trial, which revealed the drug's ability to continue improvement for several non-invasive fibrosis ...
Investing.com -- Altimmune Inc (NASDAQ:ALT) stock plunged 22.8% Friday after the company released 48-week data from its Phase 2b trial of pemvidutide for metabolic dysfunction-associated ...
Get the archive from the release page. x86_64 and ARM64 (AArch64) architectures are available. Please note that I was not able to test the ARM64 one myself. Run the AltAppSwitcher.exe (preferably as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback